Business Wire

OR-LATTICE-SEMICONDUCTOR

24.6.2020 22:02:04 CEST | Business Wire | Press release

Share
Lattice Reinvents the Low Power, General-Purpose FPGA with New Certus-NX

Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the new Lattice Certus™-NX family of FPGAs. The devices lead the general-purpose FPGA market in I/O density, delivering up to twice the I/O density per mm2 in comparison to similar competing FPGAs, and provide best-in-class power savings, small size, reliability, instant-on performance, and support fast PCI Express (PCIe) and Gigabit Ethernet interfaces to enable data co-processing, signal bridging, and system control. Certus-NX FPGAs target a range of applications, from data processing in automated industrial equipment to system management in communications infrastructure. The Certus-NX devices are the second family of FPGAs developed on the Lattice Nexus™ platform, the industry’s first low power FPGA platform using 28 nm FD-SOI process technology. With the launch of Certus-NX, Lattice marks the release of the second device family developed under Lattice’s new product development strategy in just six months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005722/en/

“Certus-NX delivers unique and innovative capabilities that set it apart,” said Linley Gwennap, Principal Analyst at The Linley Group. “Compared to competing FPGAs of similar gate counts, Lattice offers a much smaller package, greater I/O density, and lower power.”

“Thanks to innovations at the system, architecture, and circuit level in our Lattice Nexus development platform, we are releasing new products at a faster pace and giving our customers more options to choose from as they evaluate the performance and power needs of their applications,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “Certus-NX has clearly reset expectations for what developers should look for in general-purpose FPGAs by providing a compelling blend of parallel processing performance and flexible I/O support that enables creative new device designs.”

Technology trends like industrial automation and 5G have developers across markets looking to add processing and connectivity to applications that operate at the network Edge. To successfully support these trends, devices require low power processing hardware with support for popular interfaces like PCIe and Gigabit Ethernet. Device developers also need easy-to-use development platforms from a single source that provide the hardware, software, and IP they need to get products to market quickly.

“As an FPGA-centric design house, we’re seeing increasing adoption of serial protocols like PCIe and Gigabit Ethernet for chip-to-chip connectivity in many end applications, including 5G and IoT systems,” said Sanjeev Kumar, CEO, Logic Fruit Technologies. “The latest generation of FPGAs by Lattice, Certus-NX, supports these standards and provides a high density of I/Os while keeping power consumption and overall device footprint in check. These FPGAs will allow us to rapidly adapt to the challenging and evolving connectivity and performance needs of our customers.”

Key features of the Lattice Certus-NX FPGA family include:

  • Up to 3x smaller form factor – Certus-NX FPGAs easily fit into compact designs with minimal impact on overall design footprint. For example, Certus-NX FPGAs can enable a complete PCIe solution with a size of only 36 mm2 . Even when using the smallest package available in the family, Certus-NX FPGAs deliver up to twice the I/O density per mm2 in comparison to similar competing FPGAs to enable greater design flexibility and robust support for bridging applications.
  • Robust I/O interfacing capability – Certus-NX developers will have access to Lattice’s extensive IP library. Notable IP blocks available on Certus-NX include:
    • 1.5 Gbps differential I/O with performance that is up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3. Developers can test these IP blocks on Certus-NX development boards for the fast implementation of interfaces commonly used in Certus-NX FPGAs’ target applications.
  • Robust authentication and encryption – To secure the devices’ bitstream against unauthorized access/alteration/copying, Certus-NX FPGAs support AES-256 with ECDSA authentication to protect devices throughout their lifecycles. Currently, Certus-NX devices are the smallest FPGAs on the market to support ECDSA.

  • Up to 4x lower power consumption – Certus-NX FPGAs use a programmable back bias to enable user-selectable high performance or low power operating modes, depending on the needs of their application. The devices can provide power consumption up to 4x lower than similar FPGAs.
  • Instant-on performance – The devices also offer ultra-fast device configuration from SPI memory that is up to 12x faster than similar competing FPGAs, with individual I/Os able to configure in just 3 ms, and full-device startup in only 8-14 ms depending on device capacity.
  • High reliability – Reliable performance is key for safety-critical industrial and automotive applications where devices must perform as expected to avoid damage/injury. Certus-NX FPGAs offer up to 100 times better soft-error rate (SER) performance than similar FPGAs. Certus-NX FPGAs are temperature-rated for use in industrial applications. They also support ECC and SEC in hardware.
  • Ease of use/design – Certus-NX FPGAs support Lattice Radiant® software, an easy-to-use, unified FPGA design environment that integrates best-in-class tools and features to help users develop their applications quickly and efficiently.

Lattice has already shipped sample devices to select customers. For more information, please visit http://www.latticesemi.com/Certus-NX .

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.

For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo or Youku .

Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye